Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

7Total
P 1 (5)
P 2 (2)

Trial Status

Recruiting4
Withdrawn1
Active Not Recruiting1
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05501704Phase 2Recruiting

ETHAN - ET for Male BC

NCT06586957Phase 1Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT07340541Phase 2Recruiting

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT05383196Phase 1Active Not Recruiting

Onvansertib + Paclitaxel In TNBC

NCT06264921Phase 1Terminated

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

NCT05868226Phase 1Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program

NCT04602117Phase 1Withdrawn

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Showing all 7 trials

Research Network

Activity Timeline